Literature DB >> 32379805

Genetic risk scores for coronary artery disease and its traditional risk factors: Their role in the progression of coronary artery calcification-Results of the Heinz Nixdorf Recall study.

Sonali Pechlivanis1, Susanne Moebus1,2, Nils Lehmann1, Raimund Erbel1, Amir A Mahabadi3, Per Hoffmann4,5, Karl-Heinz Jöckel1, Markus M Nöthen4, Hagen S Bachmann6.   

Abstract

BACKGROUND: Atherosclerosis is the primary cause of coronary artery disease (CAD). Several observational studies have examined the association of traditional CAD risk factors with the progression of coronary artery calcification (CAC). In our study we investigated the effect of 11 different genetic risk scores associated with CAD and CAD risk factors on the progression of CAC. METHODS AND
RESULTS: We included 3097 participants from the Heinz Nixdorf Recall study who had available CAC measurements at baseline (CACb) and at the 5-year follow-up (CAC5y). A weighted genetic risk score for CAD and each of the CAD-associated risk factors was constructed. Multiple regression analyses were applied to i) the difference between the observed log(CAC5y+1) (log(obs)) and expected log(CAC5y+1) (log(exp)) at the 5-year follow-up following the individual's log(CACb+1) percentile for the time between scans (log(obs)-log(exp)) and ii) the 5-year CAC progression, defined as 5*(log(CAC5y+1)-log(CACb+1))/time between the scans, adjusted for age, sex, and log(CACb+1) as well as for risk factors. The median percent deviation from the expected (CAC5y+1) and the 5-year progression of (CAC+1) in our study were 0 (first quartile: Q1; third quartile: Q3: -0.32; 0.48) and 45.4% (0%; 171.0%) respectively. In the age-, sex- and log(CACb+1)-adjusted model, the per-standard deviation (SD) increase in CAD genetic risk score was associated with the percent deviation from the expected (CAC5y+1) (9.7% (95% confidence interval: 5.2%; 14.5%), p = 1.6x10-5) and the 5-year progression of CAC (7.1% (3.0%; 11.4%), p = 0.0005). The CAD genetic risk score explains an additional 0.6% of the observed phenotypic variance for "log(obs)-log(exp)" and 0.4% for 5-year progression of CAC. Additionally, the per-SD increase in the CAC genetic risk score was associated with the percent deviation from the expected (CAC5y+1) (6.2% (1.9%; 10.8%, p = 0.005)) explaining an additional 0.2% of the observed phenotypic variance. However, the per-SD increase in the CAC genetic risk score was not associated with the 5-year progression of CAC (4.4% (0.4%; 8.5%), p = 0.03) after multiple testing. Adjusting for risk factors did not change the results. None of the other genetic risk scores showed an association with the percent deviation from the expected (CAC5y+1) or with the 5-year progression of CAC.
CONCLUSIONS: The association of the CAC genetic risk score and the CAD genetic risk score provides evidence that genetic determinants for CAC and CAD influence the progression of CAC.

Entities:  

Year:  2020        PMID: 32379805     DOI: 10.1371/journal.pone.0232735

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  3 in total

1.  Genetics of adrenergic signaling drives coronary artery calcification.

Authors:  Jessica Gambardella; Xujun Wang; Pasquale Mone; Wafiq Khondkar; Gaetano Santulli
Journal:  Atherosclerosis       Date:  2020-08-17       Impact factor: 5.162

2.  Association between atherogenic index of plasma and coronary artery calcification progression in Korean adults.

Authors:  Ji Sun Nam; Min Kyung Kim; Joo Young Nam; Kahui Park; Shinae Kang; Chul Woo Ahn; Jong Suk Park
Journal:  Lipids Health Dis       Date:  2020-07-02       Impact factor: 3.876

3.  Association between HindIII (rs320) variant in the lipoprotein lipase gene and the presence of coronary artery disease and stroke among the Saudi population.

Authors:  Neda M Bogari; Ashwag Aljohani; Anas Dannoun; Osama Elkhateeb; Masimo Porqueddu; Amr A Amin; Dema N Bogari; Mohiuddin M Taher; Faruk Buba; Reem M Allam; Mustafa N Bogari; Francesco Alamanni
Journal:  Saudi J Biol Sci       Date:  2020-06-24       Impact factor: 4.219

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.